The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Research Funding - Abbvie (Inst); Alliance Oncology (Inst); Amgen (Inst); Ascentage Pharma Group (Inst); AstraZeneca (Inst); Bayer (Inst); Biodesix (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); EMD Serono (Inst); Evelo Biosciences (Inst); Exact Sciences (Inst); Genentech/Roche (Inst); Hutchison MediPharma (Inst); Immunomedics (Inst); Janssen Biotech (Inst); Lilly (Inst); MT Group (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Polynoma (Inst); Seagen (Inst); Tesaro (Inst); TG Therapeutics (Inst); Vaccinex (Inst)
Interim subgroup analysis for response by PD-L1 status of CLASSICAL-Lung, a phase Ib/II study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC.
 
Michael Rahman Shafique
Consulting or Advisory Role - GlaxoSmithKline
Research Funding - Amphivena (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Merck Serono (Inst); Nektar (Inst); PsiOxus Therapeutics (Inst); Vaccinex (Inst)
Travel, Accommodations, Expenses - Janssen Research & Development; Nektar; Vaccinex
 
Terrence Lee Fisher
Employment - Vaccinex
Stock and Other Ownership Interests - Vaccinex
Patents, Royalties, Other Intellectual Property - Patent author, Vaccinex, Inc.
 
Elizabeth E. Evans
Employment - Vaccinex
Stock and Other Ownership Interests - Vaccinex
Patents, Royalties, Other Intellectual Property - Inventor on following patents: Treatment of cancer with a semaphorin-4d antibody in combination with an epigenetic modulating agent. U.S. Provisional Patent Application No. 62/473,731 Use of Semaphorin-4D inhibitory molecules in combination with an im (Inst)
 
John E. Leonard
Employment - Vaccinex
Leadership - Vaccinex
Stock and Other Ownership Interests - Vaccinex
Travel, Accommodations, Expenses - Vaccinex
 
Desa Rae Electa Pastore
Stock and Other Ownership Interests - Vaccinex
 
Crystal L. Mallow
Employment - Vaccinex
 
Ernest Smith
Employment - Vaccinex
Leadership - Vaccinex
Stock and Other Ownership Interests - Vaccinex
Patents, Royalties, Other Intellectual Property - Vaccinex
 
Andreas Schröder
Employment - Merck KGaA
Stock and Other Ownership Interests - Merck KGaA
 
Kevin M. Chin
Employment - EMD Serono
Stock and Other Ownership Interests - Merck KGaA
 
Joseph Thaddeus Beck
No Relationships to Disclose
 
Megan Ann Baumgart
Consulting or Advisory Role - Bristol-Myers Squibb
 
Ramaswamy Govindan
Honoraria - Abbvie; Genentech/Abbvie; Geneplus
Consulting or Advisory Role - Abbvie; Achilles Therapeutics; Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Celgene; EMD Serono; Genentech/Roche; GlaxoSmithKline; Ignyta; Janssen; Jounce Therapeutics; Lilly; Merck Serono; Nektar; Pfizer; Phillips Gilmore Oncology; Roche
 
Nashat Y. Gabrail
No Relationships to Disclose
 
Rachel E. Sanborn
Honoraria - Amgen; AstraZeneca
Consulting or Advisory Role - Abbvie; Amgen; ARIAD; AstraZeneca; Celldex; Genentech/Roche; Peregrine Pharmaceuticals; Seagen; Takeda
Research Funding - Bristol-Myers Squibb (Inst); MedImmune (Inst); Merck
Travel, Accommodations, Expenses - AstraZeneca; Five Prime Therapeutics; Janssen Oncology
 
Alexander I. Spira
Stock and Other Ownership Interests - Lilly
Honoraria - Amgen; AstraZeneca/MedImmune; CytomX Therapeutics; Merck; Takeda
Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); incyte; Novartis
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); Arch Therapeutics (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); LAM Therapeutics; LAM Therapeutics (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); Newlink Genetics (Inst); Novartis (Inst); Plexxikon (Inst); Roche (Inst); Takeda (Inst); Trovagene (Inst)
 
Nagashree Seetharamu
Consulting or Advisory Role - Amgen; AstraZeneca; Genentech; Takeda
 
Yanyan Lou
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer
 
Aaron Scott Mansfield
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Abbvie; Roche
 
Jonathan Wade Goldman
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech/Roche; Lilly; Trovagene; Vortex Biosciences
Speakers' Bureau - Merck
Research Funding - Abbvie; Array BioPharma; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca/MedImmune; Bristol-Myers Squibb; Celgene; Clovis Oncology; Corvus Pharmaceuticals; Genentech/Roche; Lilly; Spectrum Pharmaceuticals; Threshold Pharmaceuticals
 
Maurice Zauderer
Employment - Vaccinex
Leadership - Vaccinex
Stock and Other Ownership Interests - Vaccinex
Patents, Royalties, Other Intellectual Property - inventor on several patents assigned to Vaccinex, Inc. No royalty or other direct financial interest in patent.